论文部分内容阅读
选择已确诊的初发2型糖尿病患者189例,随机分为A组、B组:A组(96例)给予单纯预混胰岛素治疗3月;B组(93例)给予预混胰岛素加用二甲双胍治疗3月。所有患者均无用药禁忌症,分别记录2组血糖达标时间、达标时日胰岛素用量、低血糖反应以及体重、糖化血红蛋白(HbA1c),空腹血糖(FPG),餐后两小时血糖(2hPG)变化。结果:预混胰岛素联合二甲双胍治疗血糖达标时间快、达标时胰岛素用量少,低血糖发生率低,对体重影响小。结论:预混胰岛素联合二甲双胍治疗初发2型糖尿病优于其他治疗方案,有利于糖尿病患者长期血糖达标。
A total of 189 patients with newly diagnosed type 2 diabetes mellitus were selected and randomly divided into group A and group B. Patients in group A (96 patients) were treated with premixed insulin for 3 months. Patients in group B (93 patients) were given premixed insulin plus metformin Treatment of March. All patients had no contraindications of drug use. The blood glucose up-time, the daily insulin dosage, the hypoglycemic reaction and body weight, HbA1c, fasting blood glucose (FPG) and 2-hour postprandial blood glucose (2hPG) were recorded. Results: The premixed insulin combined with metformin fasting blood glucose compliance time, the standard insulin dosage less, low incidence of hypoglycemia, little effect on body weight. Conclusion: Pre-mixed insulin and metformin in the treatment of newly diagnosed type 2 diabetes is superior to other treatment options, which is in favor of long-term blood glucose compliance in patients with diabetes mellitus.